<DOC>
	<DOC>NCT03009799</DOC>
	<brief_summary>This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the signs and symptoms of adenoviral conjunctivis</brief_summary>
	<brief_title>Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)</brief_title>
	<detailed_description>A multicenter, double masked, parallel, randomized 1:1 ratio clinical investigation comparing carrageenan eye drops (NCX 4240) versus placebo up to 21 days. Total expected number of patients: 148 Randomization: patients will be randomized 1:1 between: - Group A: eye drops containing iota-carrageenan (NCX 4240), 1 drop in each eye 8 times/day for 7 days (mandatory) then at least 4 to 8 times/day for the next 14 days until Day 21 or - Group B: ocular lubricant eye drop (carmellose 0.5% sterile solution) 1 drop in each eye 8 times/day for 7 days (Mandatory), then 4 to 8 times/day for the next 14 days until Day 21.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Inclusion</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>With unior bilateral acute adenoviral conjunctivis as diagnostised with adenoplus test Conjunctivis signs and symptoms in at least one eye AND positive adenoplus test in at least one eye whatever signs/symptoms and positive adenoplus test are from the same eye or not Negative results with adenoplus test in both eyes a suspected bacterial, fungal, herpes, chlamydia or acanthamoeba coinfection, based on clinical investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenoviral conjunctivis</keyword>
	<keyword>iota-carrageenan</keyword>
</DOC>